Kwikaton

Vildagliptin, the active ingredient in Kwikaton, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Kwikaton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kwikaton (vildagliptin) acts on the incretin pathway to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - HbA1c reduction: contributes to a measurable decrease in glycated haemoglobin. - Adjunct to diet and exercise: enhances the effect of lifestyle interventions when combined with other antidiabetic agents.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea: occasional mild stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms. - Arthralgia: joint pain without swelling. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Bullous pemphigoid: blistering skin disorder. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Acute kidney injury: reduced renal function in susceptible patients.

Patients should be evaluated for specific risk factors before initiating therapy. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: monitor for hypoglycaemia, especially when combined with other agents. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; monitor glucose closely. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Vildagliptin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Insulin: may cause severe hypoglycaemia. - Sulfonylureas (e.g., glipizide, glyburide): heightened risk of low blood glucose.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may affect blood glucose control. - Rifampin: enzyme induction can reduce vildagliptin exposure. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Digoxin: possible increase in serum levels; observe for toxicity. - Beta‑blockers: may mask hypoglycaemia symptoms; advise careful monitoring.